Arsenal is committed to improving the efficiency and efficacy of the healthcare industry and thereby patient outcomes. Arsenal believes that the combination of advances in biomedical science and information technology provides a unique opportunity to build important companies while making a significant improvement in the quality of care available to patients around the world. Central to Arsenal's mission is the creation of value for all our constituencies: our portfolio company clients, management teams and employees, our investors, and society.
Targeted Areas of Focus
Arsenal concentrates its investments in two specific healthcare segments: biopharmaceutical research, development and commercialization; and business services to providers and payors. Arsenal invests in technology-enabled business services companies that provide essential capabilities to the multitude of organizations within these targeted segments.
Most healthcare companies and institutions are seeking to optimize or restructure their organization or workflows to improve efficiency and better serve their markets and patients. Arsenal's technology-enabled business service companies serve as catalysts of these critical endeavors and strategically important operational partners.
Arsenal Healthcare Strategic Company Building
Arsenal professionals include some of the most respected individuals in critical areas of healthcare. Arsenal's team includes leaders in biomedical science, information services and corporate management. Current and previous portfolio companies have become recognized as transformational leaders and critical strategic partners to the organizations that they serve.
In Healthcare, Arsenal has invested in eight platform companies and assisted its portfolio companies in executing 31 add-on acquisitions which:
Have helped initiate and oversee ~10,000 clinical trials
Have been involved in 90% of all recent FDA approved NMEs and biologics
Serve over 200 academic medical centers and over 3,000 U.S. hospitals
Serve virtually all major bio-pharma companies and CROs
Amongst the capabilities provided to portfolio companies are involvement by Arsenal’s bio-medical and information technology professionals, independent guidance from its Healthcare Advisory Board and pro-active assistance in consummating and integrating strategic acquisitions to augment critical portfolio company capabilities.
Arsenal helps to create opportunities for its portfolio companies across our extensive network of provider, payor and bio-pharma clients.
NEW YORK, August 18, 2016 – Arsenal Capital Partners, a New York based private equity firm, announced today that its portfolio company WIRB-
Arsenal Capital Partners is a specialized private equity firm that invests in the U.S. middle market with a narrow and deep focus in two sectors, Specialty Industrials and Healthcare. Our philosophy is to partner with talented management teams, provide them with access to world-class operating resources and patient capital, and develop positive, open and constructive relationships that foster long-term value creation.